secwatch.observer — SEC 8-K summary
======================================

Issuer:     TFF Pharmaceuticals, Inc. (—)
CIK:        0001733413
Form:       8-K
Filed at:   2023-11-22T23:59:59+00:00
Accession:  0001213900-23-089654
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TFF Pharmaceuticals shareholders approve reverse stock split (1:2 to 1:30) and authorize 180M shares
--------------------------------------------------------------------------------

- Authorized common stock increased to 180 million shares via Charter Amendment.
- Reverse split approved; ratio range 1:2 to 1:30, exact ratio to be set by Board.
- Directors elected: Harlan Weisman, Brandi Roberts, Robert S. Mills, Stephen C. Rocamboli.
- Marcum LLP ratified as independent registered public accounting firm for FY2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733413/000121390023089654/0001213900-23-089654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733413/000121390023089654/ea188953-8k_tffpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-089654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer